NCT05745740View on ClinicalTrials.gov

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

RC48-ADC

RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle

DRUG

Pyrotinib

Pyrotinib 400 mg by oral once a day.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT05745740 - A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | Biotech Hunter | Biotech Hunter